Amgen, looking for a path into red-hot 'molecular glues,' inks a deal with Plexium for 2 programs, potentially more
As pharma continues to seek new breakthroughs across drug modalities, few areas have garnered more interest than protein degradation. And Amgen is taking a flyer out on a small biotech that thinks its broad approach to degrader R&D could spell a fruitful relationship with the drug giant.
Amgen could pay more than $500 million in downstream milestones with an undisclosed amount upfront for access to two programs — and potentially more — from Plexium, a biotech working on an “agnostic” approach to targeted protein degradation, the companies said Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.